Research programme: fructose biphosphatase inhibitors - Viking Therapeutics

Drug Profile

Research programme: fructose biphosphatase inhibitors - Viking Therapeutics

Alternative Names: FBPase inhibitors - Viking Therapeutics

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Viking Therapeutics
  • Class Small molecules
  • Mechanism of Action Fructose bisphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Type 2 diabetes mellitus

Most Recent Events

  • 17 May 2017 Viking Therapeutics has patent protection for fructose biphosphatase inhibitors in USA, China, Korea, Israel, Mexico, Portugal, New Zealand and Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top